Primary Progressive MS. Predicting Progression. Alan J Thompson Director, UCL Institute of Neurology Queen Square
|
|
- Agatha Pitts
- 5 years ago
- Views:
Transcription
1 Primary Progressive MS Predicting Progression Alan J Thompson Director, UCL Institute of Neurology Queen Square
2 Disclosures Alan J Thompson UCL Institute of Neurology Queen Square London, UK In compliance with the Continuing Medical Education (CME) guidelines of the European Accreditation Council for Continuing Medical Education (EACCME), I declare receipt of honoraria/consultation fees from Eisai London Research Labs (advisory board member); receipt of fees and support for travel from Novartis Pharma (PPMS Steering Group member); receipt of honoraria and support for travel from Sanofi- Aventis, Serono Symposium (invited lectures); to be a consultant for DignaBiotech; to be a member of company advisory board, board of directors or other similar group for Patrick Berthoud Trust (trustee), National Hospital Development Foundation (trustee), MSIF International Medical and Scientific Board (chairman); to benefit from a relationship with a commercial enterprise as Editor-in-Chief, Multiple Sclerosis (honorarium from Sage Publications); member, editorial board for Lancet Neurology (free subscription from Elsevier); editorial board for Current Medical Literature-MS (free subscription from Remedica)
3 Primary Progressive MS Rel/Rem MS 90% Disability Secondary progressive (60%) Primary progressive (10-15%) Progressive relapsing (rare) Progressive from onset Occasional plateaus Temporary, minor improvements allowed Lublin & Reingold 1996
4 Natural History studies Age of onset 40 years (similar to SPMS) Equal sex ratio Variable course - 25% needed assistance to walk at 7.5 years - 25% were walking unaided at 25 years Tremlett et al Neurology 2005 Kremenchutsky et al Brain 2006 Confavreux et al Brain 2006
5 Sex and age at onset in the primary-progressive and relapsing populations (A) Primary -progressive from onset n=352 (B) Relapsing from onset n=2485 Tremlett et al. Neurology 2005
6 Clinical Characteristics Age of onset usually mid-forties Sex ratio equal male and female Tendency to progress in same system Rate of progression similar to SPMS Presentation Paraparesis - 83% Hemiparesis 6% Cerebellar syndrome 9% Brainstem syndrome 1% Visual loss 1% Cognition 1% (MAGNIMS Stevenson et al 2000)
7 Onset symptoms - PPMS versus relapsing onset MS Tremlett et al. Neurology 2005
8 PRIMARY PROGRESSIVE MS Relatively rare but important group Challenging to diagnose with confidence - lacks hallmark of MS Potentially important model of disease progression Considerable individual variability
9 Primary progressive MS: What can be learned from the PROMiSe Trial? (Glatiramer( Acetate in PPMS) Jerry S. Wolinsky,, Lillian Pardo, Yafit Stark, Batya Zak, Shaul Kadosh,, David Ladkani and The PROMiSe Study Group University of Texas Health Science Center Houston TEVA Neurosciences TEVA Pharmaceutical Industries
10 Can you predict disability and thereby identify those more appropriate for therapeutic intervention or enrolment into clinical trials? Clinical studies MRI studies (Disability and Cognition)
11 Clinical features and natural history of PPMS Gender Cottrell et al Brain 1999; 122: Males hatched Time from onset to death was shorter for men (----)
12 Clinical features and natural history of PPMS - Clinical presentation Cottrell et al Brain 1999; 122: Brain stem Motor Sensory cerebellar systems one two three Survival analysis to DSS 10
13 Survival analysis determined by reaching EDSS within ( ) or after (-----) 5 years Cottrell et al Brain 1999; 122:
14 Conclusions Adverse influences Shorter time to reach DSS 3 Three or more neurological systems at onset No apparent influence Age at onset, gender and type of presentation
15 The natural history of primary progressive MS in British Columbia First reported in 2005: 352/2837 (12%) had PPMS Updated in 2009: 552/5779 (10%) had PPMS
16
17 Kaplan-Meier curves showing time to (left) and age at (right) sustained EDSS 6.0 by age at disease onset. Patients with a younger age at onset took longer to reach EDSS 6.0, but these patients were also younger when reading EDSS 6.0 Koch et al. Neurology 2009
18 Kaplan-Meier curves showing time to (left) and age at (right) sustained EDSS 6.0 by sensory onset symptoms. Sensory onset symptoms were associated with both a longer time to and a higher age at EDSS 6.0 Koch et al. Neurology 2009
19 IMAGING STUDIES
20 Primary progressive MS
21 Key Questions in Progression in MS What MRI changes correlate with disability? What MRI features predict disability? Insights into underlying mechanisms of progression
22 Primary progressive MS Two studies Established PPMS followed over a long period (10 years) Small cohort of early PPMS patients studied with non-conventional techniques over 5 years Two questions What MRI changes correlate with on-going progression Can we predict progression in PPMS
23 MAGNIMS Study of PPMS 145 patients with PPMS; 5 European centres : Amsterdam, Barcelona, Bordeaux, London, Milan Evaluated at one, two, five and 10 years MRI measures T1, T2 lesion loads Atrophy measures of brain and cervical cord Clinical measures EDSS MS Functional Composite (9HPT,TWT,PASAT)
24 MAGNIMS: Baseline, Years 1 & 2 Increase in T2 lesion load; year I (14.6%), year 2 (23.3%) Decrease in brain volume; year 1 (1.3%), year 2 (1.7%) Decrease in cervical cord area (5.2% and 6.8%) Some worsening in clinical measures No correlation between clinical and MRI changes No predictor of change Baseline EDSS correlated with brain and cord atrophy Stevenson et al 1999, 2000; Ingle et al 2002
25 MAGNIMS 5 year data Involved 122 of initial cohort of 145 patients Mean age 54.7 years Mean disease duration 12.9 years EDSS: 5.6 to 6.1
26 Variability over 5 years EDSS / T2 lesion load
27 Predictors of Progression Clinical change at 5 years was predicted by At baseline: Male gender Low brain volume Two year change in T2 - number of new lesions and increased load Cord volume (reduced)
28 MAGNIMS 10 Years (5 European centres) Baseline 2 yrs 5 yrs 10 years Number of 145 patients (70%) Assess ment Imaging EDSS EDSS EDSS Imaging EDSS MSFC
29 RESULTS Clinical progression over ten years predicted by: Baseline: Male gender (0.039), shorter disease duration (0.02) Poorer score on TWT (0.001), NHPT (0.014) Lower brain volume (0.08) Over 2 years: EDSS deterioration (0.006) Reduction in brain volume (0.031) Greater number of T2 lesions (0.039)
30 Early PPMS 50 patients with PPMS Within five years of symptom onset EDSS Scanned over two sessions at baseline MRI and clinical assessment every six months for three years and at five years
31 MRI data acquired Axonal loss/oedema Neuronal viability/ membrane synthesis T1 Inflammation/gliosis T2 Inflammation Spectroscopy Triple dose Gd Atrophy T1 relaxation Neuronal/axonal viability Tissue loss MTR Myelin/oedema DTI Tissue microstructure
32 Brain Enhancement 42% patients with early PPMS (< 5 years) had at least one enhancing lesion on their baseline scan Number of enhancing lesions associated with - younger age (r=0.5, p= ) - higher T2 load ( r= 0.5, p=0.02)
33 Enhancement associated with higher disability and greater abnormality on MRI EDSS MSFC T2 load T1 load Partial Brain Volume Enhancing (18) Non-enhancing (24) P values 6.0 (range 3.5) 4.3 (range 3.5) p=0.011* -1.5 (SD 1.8) -0.4 (SD 1.1) p=0.004** 22.5ml (SD 25.0ml) 9.0ml (SD 20.1ml) p=0.005** 7.3ml (SD 10.0ml) 3.2ml (10.0ml) p=0.001** 248.3ml (SD 23.8ml) 264.1ml (SD 19.5ml) p=0.049*
34 Brain atrophy Coronal T1 WI
35 Baseline atrophy in early PPMS White matter most affected Controls (n=45) mean (range) BPF* 0.83 ( ) WMF* 0.28 ( ) GMF 0.55 ( ) Patients (n=41) mean (range) -6.2% -3.5% 0.79 ( ) 0.26 ( ) 0.52 ( ) *all differences significant at p<0.001 level allowing for age using general linear modelling
36 Results over 12 months 0-12 months BPF - SPM P < % P = WMF - SPM % P < GMF - SPM %
37 MTR MRI-visible FREE WATER POOL Magnetization transfer Free protons axon myelin MRI-invisible BOUND WATER POOL Macromolecular protons Evidence suggests that molecules associated with myelin dominate this exchange process in WM MTR map High magnetization transfer = BRIGHT Low magnetization transfer = DARK
38 MTR in early PPMS Controls Patients p NABT mean < NABT peak height < NABT peak location < NAWM mean < NAWM peak height < NAWM peak location < NAGM mean < NAGM peak height < NAGM peak location < Estimated means using General Lineal Model allowing for age and gender
39 Which MR measures correlated with clinical outcome over 3 years? Progression on EDSS over three years was associated with Rate of decrease in GM MTR mean (p=0.032) and PL (p=0.008) Rate of T2 lesion load increase (p=0.024)
40 29 Mean Grey matter MTR at baseline Grey matter MTR was the strongest predictor of progression over 3 years stable mild progression marked progression
41 Radiological measures as markers for clinical progression in early PPMS MTR Volume T2 lesion load GM WM GM WM Changes over time Y Y Y N Y Rate of change correlates with clinical change Y N N N Y Predicts future clinical change Y N N N Y
42 Conclusions MRI provides valuable insights into progression in PPMS Both grey and white matter make a contribution (possibly independently) The combination of grey matter MTR and focal T2 lesions may prove to be the strongest predictor of disability in PPMS
43 Grey matter damage predicts evolution of PPMS at 5 years Rovaris et al Brain 2006; 129:
44 Cognitive Impairment in PPMS WORSE ON Attention Verbal memory Verbal fluency Spatial reasoning MAGNIMS Camp et al. Brain 1998
45 Grey matter damage in MS Bö et al., Arch Neurol 2007 Geurts et al., JNEN 2007 Geurts & Barkhof 2008
46
47 METHODS Neuropsychological test battery Premorbid IQ An extensive neuropsychological test battery was administered to 26 patients with PPMS and 31 controls. An overall cognitive z-score was obtained Clinical and sociodemographic variables were also recorded Current IQ Verbal Performance overall cognitive z-score IQ Decline Verbal Performance Memory Story recall: immediate (/56) Story recall: delayed (/56) Figure recall: immediate (/56) Figure recall: delayed (/56) Attention/Speed of information processing PASAT SDMT z-score Executive function Hayling: total of scaled scores (/23) Brixton: errors (/54)
48 RESULTS Overall cognitive performance GM MTR (PL) showed the strongest correlation with the overall cognitive z-score, explaining 63% of the variance (β= 1.02 [95%CI: 0.65, 1.4], p<0.001). Executive function GM MTR (PH) showed the strongest correlation with the Hayling test (β= [2313.9,4320.3], p<0.001) Attention and speed of information processing function NAWM volume showed the strongest correlation with the SDMT (β= 0.48 [0.27, 0.68], p<0.001) Memory T2 lesion load showed the best correlation with a poorer performance on the Delayed Recall Test (β= [-0.3, -0.03], p = 0.021) Decline in verbal IQ GM MTR (mean) showed the strongest correlation (β= [-6.44, -1.83], p=0.001)
49 2 ASSOCIATION BETWEEN IMAGING AND COGNITIVE DYSFUNCTION overall cognitive z-score Overall cognitive performance -6 β= 1.02 (0.65, 1.40), p < GM PL MTR 34 zcog values Adjusted by yearsfitted of education Regression of the overall cognitive z-score over GM PL MTR 35
50 CONCLUSIONS GM MTR showed the strongest correlation with overall cognitive performance However, T2 lesion load and GM MTR and NAWM volumes are also important for specific cognitive impairments
51 Conclusions Predictors of outcome Clinical Poor - Multisystem presentation (rare) - Rapid early progression Good - Sensory presentation - Younger age of onset (caveat) Imaging - Enhancement at baseline (possible) - Reduced GM MTR and high T2 lesion load - Early worsening in GM MTR and T2 lesion load
52 Acknowledgements The Wellcome Trust, MSIF, NIHR, MS Ttrust MS Society of GB & NI PPMS Team Olga Ciccarelli, Val Stevenson, Jaume Sastre, Gordon Ingle, Zhaleh Khaleeli, Francesco Manfredonia, Benedetta Bodini, CarmenTur. MS Team NMR Unit D Miller, X.Golay. M Ron, T Yousry, A Toosy, C Wheeler-Kingshott, MAGNIMS
ORIGINAL CONTRIBUTION. Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis
ORIGINAL CONTRIBUTION Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis Francesco Manfredonia, MD; Olga Ciccarelli, PhD; Zhaleh Khaleeli, MRCP;
More informationComplementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS
Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS Carmen Tur, Zhaleh Khaleeli, Olga Ciccarelli, Daniel R Altmann, Mara Cercignani, D H Miller, A J Thompson To
More informationMULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson
MULTIPLE SCLEROSIS IN 2015 Managing the complexity of multiple sclerosis Olga Ciccarelli and Alan Thompson The application of imaging biomarkers has provided new insights into the mechanisms of damage
More informationECTRIMS-MAGNIMS MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS FELLOWS Awardees
ECTRIMS-MAGNIMS MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS FELLOWS 2017 Awardees Soheil Damangir, PhD Optimizing crowd-sourced solutions toward generating large reference datasets for WM lesion segmentation
More informationMRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS
MRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS Maria A. Rocca Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute
More informationECTRIMS-MAGNIMS MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS FELLOWS Awardees
ECTRIMS-MAGNIMS MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS FELLOWS 2018 Awardees Alberto Calvi, PhD Slowly Evolving Lesions (SELs) in multiple sclerosis Queen Square Multiple Sclerosis Centre, University
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of
More informationMEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationMRI in MS: the radiologist perspective
MS Preceptorship - Updating Knowledge in Multiple Sclerosis - June, 1-3 2010 Barcelona MRI in MS: the radiologist perspective Àlex Rovira Unidad de Resonancia Magnética Servicio de Radiología Hospital
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationVisualisation of cortical MS lesions with MRI need not be further improved: Yes
Controversies in Multiple Sclerosis Visualisation of cortical MS lesions with MRI need not be further improved: Yes Jeroen J.G. Geurts [1] & Declan T. Chard [2] 1. Dept. of Anatomy & Neurosciences, VUmc
More information24-25 February Siena, Italy
WORKSHOP FINAL PROGRAMME AND ABSTRACT BOOK Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis 24-25 February 2016 - Siena, Italy Clinical and research application
More informationAssessing treatment outcomes in multiple sclerosis trials and the clinical
1 Assessing treatment outcomes in multiple sclerosis trials and the clinical setting Working title: Outcomes in multiple sclerosis Carmen Tur 1, Marcello Moccia 1,2, Frederik Barkhof 1,3,4,5, Jeremy Chataway
More informationCognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis. Background
Cognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis Victoria A Levasseur 1,2, Samantha Lancia 1, Gautam Adusumilli 1, Zach Goodman 1, Stuart D. Cook 3, Diego Cadavid 4, Robert T.
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More informationReview Article Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations
Multiple Sclerosis International Volume 2013, Article ID 627870, 16 pages http://dx.doi.org/10.1155/2013/627870 Review Article Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations Justin
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationNeurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy
Nicola De Stefano Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy Declared receipt of honoraria or consultation fees from Novartis,
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Use of MRI in Clinical Decision- Making
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationGiancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
More informationMagnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis
doi:10.1093/brain/awh654 Brain (2005), 128, 2911 2925 Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis K. T. M. Fernando, 1,3 D. J. Tozer, 1 K. A. Miszkiel,
More informationThe natural history of secondary progressive multiple sclerosis
See Editorial Commentary, p 944 1 Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada 2 Department of Neurology, University Medical Centre Groningen, University
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationPlenary Session 2 Psychometric Assessment. Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo
Plenary Session 2 Psychometric Assessment Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo Reliability Validity Group Discrimination, Sensitivity Validity Association
More informationMS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationEfficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific
More informationECTRIMS NEWSLETTER September Letter from the President
ECTRIMS NEWSLETTER September 2018 Letter from the President Already we are in to the second half of 2018 and as the autumn approaches we are looking forward to the ECTRIMS 2018 Congress, which is being
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationEAN Amsterdam June 23-27, 2017
EAN 2017 Amsterdam June 23-27, 2017 MS Nowadays-new goals Giancarlo Comi Dept. of Neurology & Institute of Experimental Neurology Università Vita Salute S.Raffaele, Milano European Charcot Foundation Disclosure
More informationQuantitative Neuroimaging- Gray and white matter Alteration in Multiple Sclerosis. Lior Or-Bach Instructors: Prof. Anat Achiron Dr.
Quantitative Neuroimaging- Gray and white matter Alteration in Multiple Sclerosis Lior Or-Bach Instructors: Prof. Anat Achiron Dr. Shmulik Miron INTRODUCTION Multiple Sclerosis general background Gray
More informationDiagnostic Criteria, Clinical Courses, and Rating Scales in MS
Diagnostic Criteria, Clinical Courses, and Rating Scales in MS Introduction and Objectives Introduction This module will focus on diagnostic tools utilized in randomized clinical trials (RCTs) in MS. Diagnostic
More informationMagnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis.
Chapter 10 (pp 139-167) of Multiple Sclerosis 2 - Blue Books of Practical Neurology, vol. 27. J.H Noseworthy, W.I. McDonald (eds.). Elsevier Science (USA), 2003. Magnetic Resonance Imaging and Spectroscopy:
More informationSpinal cord MR imaging in Multiple Sclerosis
43ème CONGRÈS ANNUEL de la Société Française de NeuroRadiologie 30 mars au 1 er avril 2016 Novotel Paris Tour Eiffel Spinal cord MR imaging in Multiple Sclerosis Àlex Rovira Unitat de Neurorradiología.
More informationEarly development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes
DOI: 10.1093/brain/awh126 Brain (2004), 127, 1101±1107 Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes
More informationNeuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS
Neuroimaging and Other Biomarkers MRI for Diagnosis, Prognosis and Treatment Decisions in MS Eric Klawiter, MD MSc Massachusetts General Hospital May 30, 2014 Disclosures and Funding Disclosures: Consulting
More informationTable e-1: Patient Level Baseline Characteristics
Table e-1: Patient Level Baseline Characteristics *= Subject not transplanted on study due to heparin induced thrombocytopenia following mobilization. ALE = Alemtuzumab; AZA = Azathioprine; CY = Cyclophosphamide;
More informationEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
RESEARCH ARTICLE Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials Vissia Viglietta 1, David Miller 2, Amit Bar-Or 3, J.
More informationPrimary progressive multiple sclerosis: a 5-year clinical and MR study
DOI: 10.1093/brain/awg261 Advanced Access publication August 5, 2003 Brain (2003), 126, 2528±2536 Primary progressive multiple sclerosis: a 5-year clinical and MR study G. T. Ingle, 1 V. L. Stevenson,
More informationAIMS M U L T I P L E S C L E R O S I S. Cognitive Issues in
Jointly provided by In collaboration with N PA w w w.c m e A I M S. o r g AIMS ADVANCES IN MULTIPLE SCLEROSIS Cognitive Issues in M U L T I P L E S C L E R O S I S A U T H O R S Ralph H. Benedict, PhD
More information1 MS Lesions in T2-Weighted Images
1 MS Lesions in T2-Weighted Images M.A. Sahraian, E.-W. Radue 1.1 Introduction Multiple hyperintense lesions on T2- and PDweighted sequences are the characteristic magnetic resonance imaging (MRI) appearance
More informationBasic Course on MRI. Clinician s Primer on Multiple Sclerosis. Expiration Date: MAY Estimated Time to Complete Activity: 3.
2 Clinician s Primer on Multiple Sclerosis Basic Course on MRI Release Date: MAY 2011 Expiration Date: MAY 2012 Estimated Time to Complete Activity: 3.0 Hours This activity is supported by an educational
More informationLong-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing remitting multiple sclerosis: the CLARITY Extension study
753365TAN0010.1177/1756285617753365Therapeutic Advances in Neurological DisordersG Comi, S CooK research-article2018 Therapeutic Advances in Neurological Disorders Original Research Long-term effects of
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org How
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationORIGINAL CONTRIBUTION. Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis
ORIGINAL CONTRIBUTION Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis Marco Rovaris, MD; Antonio Gallo, MD; Andrea Falini, MD; Beatrice Benedetti, MD; Paolo
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationInvestor Update. Downloads. Services PDF. Basel, 17 July 2017
Investor Update Basel, 17 July 2017 Roche s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and
More informationNegative prognostic impact of MRI spinal lesions in the early stages of relapsing remitting multiple sclerosis
Original Article Negative prognostic impact of MRI spinal lesions in the early stages of relapsing remitting multiple sclerosis E D Amico, F Patti, C Leone, S Lo Fermo and M Zappia Multiple Sclerosis Journal
More informationMedia Release. Basel, 10 November 2017
Media Release Basel, 10 November 2017 Roche s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis If approved, OCREVUS
More informationLongitudinal changes in diffusion tensor based quantitative MRI in multiple sclerosis
Longitudinal changes in diffusion tensor based quantitative MRI in multiple sclerosis D.M. Harrison, MD B.S. Caffo, PhD N. Shiee, MS J.A.D. Farrell, PhD P.-L. Bazin, PhD S.K. Farrell, BS J.N. Ratchford,
More informationRegional Grey Matter Atrophy is associated with Social Cognition impairment in Progressive Multiple Sclerosis (MS).
Escuela de Medicina Regional Grey Matter Atrophy is associated with Social Cognition impairment in Progressive Multiple Sclerosis (MS). Escuela de Medicina Tomas Labbe(1), Ethel Ciampi(2), Juan Pablo Cruz(3),
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationT he spinal cord is frequently affected, both pathologically
51 PAPER Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, R Gordon, A J Thompson, D H Miller... See end
More informationSupplementary Online Content
Supplementary Online Content Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol. Published online June
More informationWorkshop II. How to manage highly active MS patients in practice?
Workshop II How to manage highly active MS patients in practice? Gavin Giovannoni Department of Neurology Institute of Cell and Molecular Science Queen Mary University London & Barts and The London NHS
More informationEndpoints in a treatment trial in NMO: Clinician s view. Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK
Endpoints in a treatment trial in NMO: Clinician s view Anu Jacob Consultant Neurologist The Walton Centre, Liverpool,UK 1 The greatest challenge to any thinker is stating the problem in a way that will
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationRoche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis
Media Release Basel, 28 September 2017 Roche s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis OCREVUS is the first and only approved treatment
More informationMRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger
MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis E.W. Radue K. Bendfeldt Till Sprenger Medical Image Analysis Center University Hospital Basel www. miac.ch
More informationHelpful Information for evaluation of new neurological symptoms in patients receiving TYSABRI
Helpful Information for evaluation of new neurological symptoms in patients receiving TYSABRI This information is provided as an educational resource for healthcare providers and should be considered current
More informationMS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationAll relapsing multiple sclerosis patients should be managed at a specialist clinic- YES. Dr W J Brownlee FRACP 1. O Ciccarelli FRCP 1,2
All relapsing multiple sclerosis patients should be managed at a specialist clinic- YES Dr W J Brownlee FRACP 1 O Ciccarelli FRCP 1,2 1 Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation,
More informationTHE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY
THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker, II, MD University of Alabama at Birmingham June 2, 2016 DISCLOSURES Research Support: Biogen Idec; Department of
More informationTarget audience. Chair. Xxx Xxx
EXCEMED WORKSHOP The immunomodulatory role of therapeutic plasma exchange in neuromuscular and PNS diseases: a practical approach & new knowledge London, UK - 19 May 2018 The immunomodulatory role of therapeutic
More informationMAGNETIC RESONANCE IMAGING MARKERS OF LONG TERM DISABILITY IN RELAPSE-ONSET MULTIPLE SCLEROSIS PATIENTS. Leonora Kaloçi Fisniku, MBBS, MRCP(UK)
MAGNETIC RESONANCE IMAGING MARKERS OF LONG TERM DISABILITY IN RELAPSE-ONSET MULTIPLE SCLEROSIS PATIENTS Leonora Kaloçi Fisniku, MBBS, MRCP(UK) NMR Research Unit, Institute of Neurology, University College
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationA randomised, placebo-controlled trial investigating the role of Fampridine in cognitive performance of patients with multiple sclerosis.
A randomised, placebo-controlled trial investigating the role of Fampridine in cognitive performance of patients with multiple sclerosis. PRINCIPAL INVESTIGATOR: Name: Carlo Pozzilli Institution/Organization:
More informationNeuroplasticity: functional MRI techniques M.A. Rocca
Neuroplasticity: functional MRI techniques M.A. Rocca Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele
More informationPatient-reported outcomes, biomarkers and novel methodologies, and their role in the development of new multiple sclerosis medicines
Patient-reported outcomes, biomarkers and novel methodologies, and their role in the development of new multiple sclerosis medicines Frank Dahlke MD, Novartis Pharma AG on behalf of efpia 1 Patient Reported
More informationDementia in Parkinson s disease:
Dementia in Parkinson s disease: A 20 year Prospective Neuropsychological Study Sydney Multicentre Study Associate Professor Wayne GJ Reid PhD FAPS 149 newly diagnosed community living Parkinson s Disease
More informationAssociation of asymptomatic spinal cord lesions and atrophy with disability. 5 years after a clinically isolated syndrome
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome WJ Brownlee 1, DR Altmann 1,2, P Alves Da Mota 1, JK Swanton 1, KA Miszkiel 3, CAM
More informationMedia Release. Basel 12 January 2018
Media Release Basel 12 January 2018 Roche s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved
More informationThe new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers A. Petzold M.J. Eikelenboom G. Keir C.H. Polman B.M.J. Uitdehaag E.J. Thompson G. Giovannoni 04.08.2005
More informationFast Facts: Multiple Sclerosis
Fast Facts Fast Facts: Multiple Sclerosis George D Perkin and Jerry S Wolinsky Second edition 2006 Health Press Ltd. www.fastfacts.com Fast Facts Fast Facts: Multiple Sclerosis Second edition George D
More informationCOGNITIVE AND BRAIN CHANGES IN MULTIPLE SCLEROSIS
1 COGNITIVE AND BRAIN CHANGES IN MULTIPLE SCLEROSIS MARCH 27, 2017 Esther Fujiwara, Ph.D. (efujiwara@ualberta.ca) Department of Psychiatry, University of Alberta 2 Objectives 1. Identify cognitive challenges
More informationTreating MS. New medicines, strong evidence, better practice? September 2015
Treating MS New medicines, strong evidence, better practice? September 2015 1 A Treatment Revolution for RRMS Over the past 20 years there has been a revolution in treatments for relapsing remitting MS
More informationTh1/Th17 Cytokine Dysregulation during Different Stages of Multiple Sclerosis
Th1/Th17 Cytokine Dysregulation during Different Stages of Multiple Sclerosis Benjamin M. Segal, M.D. Holtom-Garrett Professor of Neurology Director, Multiple Sclerosis Program University of Michigan Disclosures
More informationT2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis
Research paper < An additional table 1 is published online only. To view this file please visit the journal online (http://jnnp.bmj.com). 1 Department of Brain Repair and Rehabilitation, Institute of Neurology,
More informationPrimary Progressive MS: Diagnosis, Clinical Course, and Long-Term Management
Primary Progressive MS: Diagnosis, Clinical Course, and Long-Term Management Consultant: AbbVie, Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Mallinckrodt, Novartis, Sanofi Genzyme, Serono, Teva
More informationGuideline for the use of beta-interferons in patients with multiple sclerosis a South African proposal
GUIDELINE Guideline for the use of beta-interferons in patients with multiple sclerosis a South African proposal Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
More informationAnxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS
ARTICLES This article addresses the Core Competency of Patient Care and Procedural Skills Anxiety and Depressive Symptoms Are Associated With Worse Performance on Objective Cognitive Tests in MS Sarah
More informationDOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : MULTIPLE SCLEROSIS THE HISTORY OF A DISEASE PDF EBOOK EPUB MOBI Page 1 Page 2 multiple sclerosis the history of a disease multiple sclerosis the history pdf multiple sclerosis the history
More informationNovartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis real-world data at AAN confirms
More informationMAGNIMS MRI in monitoring disease activity and progression
Teaching Course 3 MAGNIMS MRI in monitoring disease activity and progression Chairs: C. Enzinger (Graz, AT) N. De Stefano (Siena, IT) 7 Chances and challenges in monitoring disease activity and progression
More informationCurrent and near-term impact of biomarkers for multiple sclerosis Gavin Giovannoni
Current and near-term impact of biomarkers for multiple sclerosis Gavin Giovannoni Institute of Cell and Molecular Science Queen Mary's School of Medicine and Dentistry Barts and The London NHS Trust The
More informationAFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE
AFFIRM IN FOCUS AN INTERACTIVE OVERVIEW START HERE INTENDED USE The information in this module is being provided to you to increase your knowledge and understanding of the AFFIRM a study. Although this
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationThe invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationMRI dynamics of brain and spinal cord in progressive multiple sclerosis
J7ournal of Neurology, Neurosurgery, and Psychiatry 1 996;60: 15-19 MRI dynamics of brain and spinal cord in progressive multiple sclerosis 1 5 D Kidd, J W Thorpe, B E Kendall, G J Barker, D H Miller,
More informationEpidemiology, Diagnosis, Natural History & Clinical Course
Epidemiology, Diagnosis, Natural History & Clinical Course Multiple Sclerosis Immune-mediated, chronic, inflammatory disease precipitated by unknown environmental factors in genetically susceptible individuals
More informationNEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS
NEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS Jeffrey A. Cohen, MD Director, Experimental Therapeutics Mellen MS Center Neurological Institute Cleveland Clinic 2018 Regional MS Summit 30 June 2018 Disclosures
More informationAssessment and optimisation of MRI measures of atrophy as potential markers of disease progression in multiple sclerosis
Assessment and optimisation of MRI measures of atrophy as potential markers of disease progression in multiple sclerosis Thesis submitted for the degree of Doctor of Philosophy Valerie Anderson UCL Institute
More informationChanging EDSS progression in placebo cohorts in relapsing MS:
Changing EDSS progression in placebo cohorts in relapsing MS: A systematic review and meta-regression Christian Röver 1, Richard Nicholas 2, Sebastian Straube 3, Tim Friede 1 1 Department of Medical Statistics,
More informationMassimo Filippi * 1. Introduction
Journal of the Neurological Sciences 206 (2003) 157 164 www.elsevier.com/locate/jns MRI clinical correlations in the primary progressive course of MS: new insights into the disease pathophysiology from
More information10/3/2016. T1 Anatomical structures are clearly identified, white matter (which has a high fat content) appears bright.
H2O -2 atoms of Hydrogen, 1 of Oxygen Hydrogen just has one single proton and orbited by one single electron Proton has a magnetic moment similar to the earths magnetic pole Also similar to earth in that
More informationMRI in Differential Diagnosis. CMSC, June 2, Jill Conway, MD, MA, MSCE
MRI in Differential Diagnosis CMSC, June 2, 2016 Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC Disclosures Speaking, consulting, and/or
More informationArticles. Copyright The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised,
More information